GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Cirrhosis Liver/The GAVAPROSEC trial - J of Hepatology - Jan.26

The GAVAPROSEC trial - J of Hepatology - Jan.26

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated January 1, 2026

Quick Answer

The GAVAPROSEC trial provides critical randomized evidence addressing the management of acute gastric variceal bleeding (GVB) in patients with cirrhosis. Gastric variceal bleeding, particularly from fundal gastric varices (GOV2) or isolated gastric varices (IGV1), is a severe and life-threatening complication of portal hypertension, associated with high rebleeding rates and mortality.


The GAVAPROSEC trial provides critical randomized evidence addressing the management of acute gastric variceal bleeding (GVB) in patients with cirrhosis. Gastric variceal bleeding, particularly from fundal gastric varices (GOV2) or isolated gastric varices (IGV1), is a severe and life-threatening complication of portal hypertension, associated with high rebleeding rates and mortality. Despite guidelines recommending endoscopic glue injection for acute hemostasis, the optimal strategy for secondary prophylaxis has remained unclear due to limited robust evidence.

The trial investigated the role of pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) placement within 72 hours after stabilization in patients with acute gastric variceal bleeding. The results demonstrated that pre-emptive TIPS significantly improved rebleeding-free survival compared to standard strategies, which often involve glue obliteration combined with non-selective beta blockers. Importantly, the study found no increase in the incidence of hepatic encephalopathy, a common concern with TIPS procedures. Although no definitive overall survival benefit was observed, the high crossover rate to TIPS in the control group likely diluted the statistical power to detect a survival advantage.

The findings of the GAVAPROSEC trial emphasize the limitations of glue-based strategies, which are associated with high rebleeding rates and depend on technical expertise that may not be uniformly available. By contrast, pre-emptive TIPS offers a more effective approach to secondary prophylaxis in this high-risk population. The trial's results support the consideration of pre-emptive TIPS as a first-line strategy after initial stabilization of gastric variceal bleeding, provided that patient selection and local expertise are carefully considered.

In conclusion, the GAVAPROSEC trial represents a significant advancement in the management of acute gastric variceal bleeding. It provides strong evidence supporting the use of pre-emptive TIPS to improve clinical outcomes, particularly rebleeding-free survival, in a population with historically poor prognoses. This trial is likely to influence future guidelines and clinical practice, offering a more standardized approach to this challenging condition.

Related Q&A

POCUS-Guided AKI Management in Cirrhosis: Hepatology | July 2026

Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...

A Novel Pro-Resolving Target (Annexin A1) for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Distal Esophageal Varices in Fontan Circulation: Hepatology | May 2026

Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...

Annexin A1-A Novel Pro-Resolving Target for ACLF: Hepatology | May 2026

Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...

Simvastatin Improves Survival After Variceal Bleeding in Cirrhosis: AJG | July 2026

Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...

Pre-Emptive CRRT Improves Outcomes in ALF with Cerebral Oedema: AP&T | June 2026

Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer